Plain-English translation of NCT05922930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach using TROP2 CAR engineered cord blood-derived NK cells—specialized immune cells that are grown in the lab to recognize and attack cancer cells. The cells are delivered directly into the belly (peritoneal cavity) where ovarian, pancreatic, and certain other cancers often live. Researchers want to see if this treatment is safe and whether it can help people whose cancers have stopped responding to standard chemotherapy.
Many patients with ovarian and pancreatic cancers find that their cancers stop responding to platinum-based chemotherapy, leaving them with few good treatment options. This medication takes a different approach by harnessing the body's own immune system to fight cancer in a new way, potentially offering hope to patients who have run out of conventional choices.
You will receive chemotherapy ( and ) for 3 days to prepare your body, followed by a single infusion of the engineered immune cells delivered directly into your abdomen through a special port. You will then visit the study clinic up to 16 times over several months for blood draws, scans, biopsies, and questionnaires about how you're feeling. The study will track whether the cells persist in your body and whether your cancer shrinks.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States